192 related articles for article (PubMed ID: 1329411)
1. Visceral and cutaneous leishmaniasis in an European paediatric population.
Mattot M; Ninane J; Bigaignon G; Vermylen C; Cornu G
Acta Clin Belg; 1992; 47(4):231-7. PubMed ID: 1329411
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case.
Gomes MAF; Medeiros LLC; Lobo FPD; Wanderley NRS; Matos APR; Jácome TDN; Monteiro MGL; Luz KG
Rev Soc Bras Med Trop; 2018; 51(3):393-396. PubMed ID: 29972577
[TBL] [Abstract][Full Text] [Related]
3. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
4. Pediatric visceral leishmaniasis in southern France.
Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
[TBL] [Abstract][Full Text] [Related]
5. Kala azar with disseminated dermal leishmaniasis.
Kumar PV; Sadeghi E; Torabi S
Am J Trop Med Hyg; 1989 Feb; 40(2):150-3. PubMed ID: 2919725
[TBL] [Abstract][Full Text] [Related]
6. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
7. Treatment of kala azar.
Ozsoylu S
Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997
[No Abstract] [Full Text] [Related]
8. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
[No Abstract] [Full Text] [Related]
9. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
Mohammadzadeh M; Behnaz F; Golshan Z
J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of clinical and laboratory findings of adult visceral leishmaniasis cases].
Ural S; Kaptan F; Sezak N; El S; Örmen B; Türker N; Demirdal T; Vardar İ; Özkan Çayıröz P; Çakalağaoğlu F
Mikrobiyol Bul; 2015 Oct; 49(4):586-93. PubMed ID: 26649416
[TBL] [Abstract][Full Text] [Related]
11. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
12. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
[TBL] [Abstract][Full Text] [Related]
14. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
15. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections.
Silveira FT; Lainson R; Shaw JJ; De Souza AA; Ishikawa EA; Braga RR
Trans R Soc Trop Med Hyg; 1991; 85(6):735-8. PubMed ID: 1801340
[TBL] [Abstract][Full Text] [Related]
17. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
18. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
19. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba G; Khalid M
Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
[No Abstract] [Full Text] [Related]
20. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
Layegh P; Rahsepar S; Rahsepar AA
Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]